| Headquarters | Marlborough, MA |
|---|---|
| Founded | 1979 |
| Market Cap | $104B (2024) |
| Employees | 45,000+ |
| Key Product | Vercise DBS |
| NYSE | BSX |
Boston Scientific (NYSE: BSX) is a global medical device leader developing innovative technologies for the treatment of cardiovascular, neurological, and other conditions. The company was founded in 1979 and has grown to become one of the largest medical device companies worldwide with a market cap exceeding $130 billion as of 2026[1].
In the field of neurodegeneration, Boston Scientific is primarily known for its Deep Brain Stimulation (DBS) systems, which are used to treat Parkinson's Disease, Essential Tremor, and Dystonia. The company's Vercise DBS platform represents a generation of advanced neurostimulation technology with directional leads and sophisticated programming capabilities[2].
Boston Scientific is a large, diversified medical device company:
| Metric | Value |
|---|---|
| IPO | 1992 (NYSE: BSX) |
| Market Cap | ~$130B (2026) |
| 2025 Revenue | $15B+ |
| R&D Investment | ~$1.5B annually |
| Employees | 45,000+ |
By Segment:
Neuromodulation specifically:
Boston Scientific's neuromodulation business, including DBS, represents a significant and growing portion of company revenue:
Investment in DBS:
Competitive Position:
DBS is strategically important to Boston Scientific for several reasons:
High-growth market: DBS represents one of the fastest-growing segments in neuromodulation
Cross-selling opportunities: DBS patients often require other Boston Scientific products
Technology platform: DBS technology applicable to other neurological conditions
Premium pricing: Advanced features support premium pricing
Boston Scientific's Vercise family of DBS devices represents the company's flagship neurostimulation platform:
| System | Indication | FDA Approval | Key Features |
|---|---|---|---|
| Vercise G | Parkinson's Disease | 2017 | Directional leads, 8-contact array |
| Vercise Genus | Parkinson's Disease | 2020 | MR conditional, extended battery life |
| Vercise Neural Navigator | Programming | 2021 | AI-assisted programming optimization |
| Vercise Carina | Future | TBA | Next-generation adaptive system |
Directional Leads: The Vercise system features a unique 8-contact directional array that enables precise current steering to target specific neural structures while minimizing side effects[3]. This represents a significant advancement over traditional omnidirectional leads.
MR Conditional: Full-body MRI compatibility allows patients to undergo diagnostic imaging procedures safely, a critical feature for aging patient populations requiring multiple imaging sessions over time[4].
Battery Options: Boston Scientific offers both rechargeable and non-rechargeable battery systems to match patient preferences and clinical needs[5].
AI Programming: The Neural Navigator platform uses machine learning algorithms to optimize stimulation parameters, potentially reducing programming time and improving clinical outcomes[6].
Current Steering: The proprietary current steering technology allows clinicians to shape the electrical field precisely, potentially reducing side effects like speech disturbance or gait difficulty while maximizing therapeutic benefit.
Chronic Stimulation: Long-term data demonstrates sustained efficacy over 5+ years of continuous stimulation in PD patients.
The Vercise Genus represents the current generation of Boston Scientific DBS technology:
Lead Design:
Implantable Pulse Generator (IPG):
Programming Interface:
Boston Scientific has developed several innovations to improve the surgical DBS implantation process:
Boston Scientific is developing next-generation adaptive DBS systems that can respond to physiological signals:
Closed-Loop Stimulation:
Brain-State Dependent Therapy:
The INTREPID study is a prospective, randomized, double-blind clinical trial evaluating the effectiveness of Vercise DBS in patients with advanced Parkinson's disease[4:1]:
The Vercise Post-Approval Study (PAS) evaluated quality of life outcomes in 161 patients:
Schuepbach WM, et al. Neurostimulation for Parkinson's Disease with early motor complications. N Engl J Med. 2013;368(7):610-622. PMID: 23438626
Deuschl G, et al. A randomized trial of deep-brain stimulation for Parkinson's Disease. N Engl J Med. 2006;355(9):896-908. PMID: 16943402
Weaver FM, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease. JAMA. 2009;301(1):63-73. PMID: 19119411
Long-term studies of Vercise DBS demonstrate sustained benefits:
Motor Function:
Quality of Life:
Cognitive Impact:
Post-market surveillance and real-world data support Vercise efficacy:
The DBS market is dominated by three major players:
| Company | DBS Products | Market Share | Key Differentiation |
|---|---|---|---|
| Medtronic | Percept, Activa, SenSight | ~50% | Largest portfolio, sensing capabilities |
| Boston Scientific | Vercise, Vercise Genus | ~25% | Directional leads, AI programming |
| Abbott | Infinity, St. Jude | ~20% | Omni-directional, Bluetooth connectivity |
| Newronika | AlphaDBS | ~5% | Adaptive/responsive stimulation |
Medtronic is the market leader in DBS with a comprehensive portfolio:
Advantages:
Boston Scientific Response:
Abbott (formerly St. Jude Medical) offers the Infinity system:
Advantages:
Boston Scientific Response:
Newronika (Italy):
Other potential entrants:
Adaptive DBS: Development of closed-loop stimulation systems that respond to real-time neural signals. This represents a paradigm shift from continuous stimulation to demand-based therapy.
Remote Programming: Telemedicine-enabled DBS adjustment capabilities, enabling patients to receive programming updates without in-person clinic visits.
New Indications: Ongoing clinical trials for:
Miniaturized Systems: Development of smaller implantable pulse generators (IPGs) to reduce surgical complexity and improve patient comfort.
Bi-directional Electrodes: Next-generation electrodes capable of both stimulating and recording neural activity, enabling data-driven therapy optimization.
Sensing Capabilities: Integration of biomarker monitoring for disease progression tracking.
2026-2027 Priorities:
2027-2028:
2028+:
Boston Scientific collaborates with academic centers and research institutions:
These collaborations support clinical evidence generation and technology innovation.
Boston Scientific has developed several innovations to improve the surgical DBS implantation process:
Optimal patient selection is critical for DBS outcomes:
Good Candidates:
Contraindications:
Preoperative Planning:
Intraoperative:
Postoperative:
Complications:
Efficacy:
| Product | FDA Status | CE Mark | Key Markets |
|---|---|---|---|
| Vercise Genus | Approved | Yes | US, EU, Japan |
| Vercise Neural Navigator | Approved | Yes | US, EU |
| Directional Leads | Approved | Yes | US, EU |
The global DBS market is projected to grow at a CAGR of 8-10% through 2030, driven by:
Boston Scientific's focus on directional leads and AI-assisted programming positions the company well to capture market share in this growing segment.
Movement Disorders (Primary):
Emerging Indications:
North America:
Europe:
Asia-Pacific:
Rest of World:
United States:
Europe:
Asia:
Directional Deep Brain Stimulation - Brown et al. Brain Stimulation 2020. 2020. ↩︎